DE3316510A1 - Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen - Google Patents

Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen

Info

Publication number
DE3316510A1
DE3316510A1 DE19833316510 DE3316510A DE3316510A1 DE 3316510 A1 DE3316510 A1 DE 3316510A1 DE 19833316510 DE19833316510 DE 19833316510 DE 3316510 A DE3316510 A DE 3316510A DE 3316510 A1 DE3316510 A1 DE 3316510A1
Authority
DE
Germany
Prior art keywords
weight
parenteral formulation
formulation according
nimodipine
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19833316510
Other languages
German (de)
English (en)
Inventor
Dieter Dr Hoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE19833316510 priority Critical patent/DE3316510A1/de
Priority to DE8484104563T priority patent/DE3461988D1/de
Priority to EP84104563A priority patent/EP0126315B1/de
Priority to AT84104563T priority patent/ATE24835T1/de
Priority to ES531995A priority patent/ES8505542A1/es
Priority to JP59086280A priority patent/JPS59206305A/ja
Priority to AU27583/84A priority patent/AU562293B2/en
Priority to BE0/212864A priority patent/BE899564A/fr
Priority to KR1019840002390A priority patent/KR920000306B1/ko
Priority to IL71744A priority patent/IL71744A/xx
Priority to GR74600A priority patent/GR81609B/el
Priority to FR8406974A priority patent/FR2545354B1/fr
Priority to IT48139/84A priority patent/IT1181804B/it
Priority to CA000453627A priority patent/CA1220424A/en
Priority to DK224184A priority patent/DK164148C/da
Priority to PT78542A priority patent/PT78542B/pt
Priority to ZA843352A priority patent/ZA843352B/xx
Publication of DE3316510A1 publication Critical patent/DE3316510A1/de
Priority to SG44489A priority patent/SG44489G/en
Priority to HK758/89A priority patent/HK75889A/xx
Priority to US07/641,323 priority patent/US5114956A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
DE19833316510 1983-05-06 1983-05-06 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen Withdrawn DE3316510A1 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DE19833316510 DE3316510A1 (de) 1983-05-06 1983-05-06 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
DE8484104563T DE3461988D1 (en) 1983-05-06 1984-04-24 Parenteral formulation of nimodipin, process for its preparation and its therapeutical use
EP84104563A EP0126315B1 (de) 1983-05-06 1984-04-24 Parenterale Formulierung von Nimodipin, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung bei der Bekämpfung von Erkrankungen
AT84104563T ATE24835T1 (de) 1983-05-06 1984-04-24 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen.
ES531995A ES8505542A1 (es) 1983-05-06 1984-04-27 Formulacion parenteral de nimodipina, un procedimiento para su preparacion, asi como su empleo en la lucha contra enfermedades
JP59086280A JPS59206305A (ja) 1983-05-06 1984-05-01 ニモジピンの非経口投与組成物
AU27583/84A AU562293B2 (en) 1983-05-06 1984-05-02 Parenteral formulation of nimodipine
IL71744A IL71744A (en) 1983-05-06 1984-05-03 Pharmaceutical parenteral formulation of nimodipine and its preparation
KR1019840002390A KR920000306B1 (ko) 1983-05-06 1984-05-03 니모디핀-함유 제제의 제조방법
BE0/212864A BE899564A (fr) 1983-05-06 1984-05-03 Composition pharmaceutique pour l'administration parenterale a base de nimodipin et procede pour sa preparation.
DK224184A DK164148C (da) 1983-05-06 1984-05-04 Parenteralt praeparat af nimodipin og fremgangsmaade til dets fremstilling
FR8406974A FR2545354B1 (fr) 1983-05-06 1984-05-04 Composition pharmaceutique pour l'administration parenterale a base de nimodipin et procede pour sa preparation
IT48139/84A IT1181804B (it) 1983-05-06 1984-05-04 Formulazione parenterale di nimodipina,procedimento per la sua produzione nonche' suo impiego nella lotta contro malattie
CA000453627A CA1220424A (en) 1983-05-06 1984-05-04 Parenteral formulation of nimodipine, a process for its preparation and its use for controlling diseases
GR74600A GR81609B (OSRAM) 1983-05-06 1984-05-04
PT78542A PT78542B (en) 1983-05-06 1984-05-04 Process for prparing a parenteral formulation containing 1,4-d y-hydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxyli of 3-beta-metoxiethyl and 5-isopropyl
ZA843352A ZA843352B (en) 1983-05-06 1984-05-04 Parenteral formulation of nimodipine,a process for its preparation and its use for controlling diseases
SG44489A SG44489G (en) 1983-05-06 1989-07-25 Parenteral formulation of nimodipin,process for its preparation and its therapeutical use
HK758/89A HK75889A (en) 1983-05-06 1989-09-21 Parenteral formulation of nimodipin, process for its preparation and its therapeutical use
US07/641,323 US5114956A (en) 1983-05-06 1991-01-15 Parenteral formulation of nimodipine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833316510 DE3316510A1 (de) 1983-05-06 1983-05-06 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen

Publications (1)

Publication Number Publication Date
DE3316510A1 true DE3316510A1 (de) 1984-11-08

Family

ID=6198265

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19833316510 Withdrawn DE3316510A1 (de) 1983-05-06 1983-05-06 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
DE8484104563T Expired DE3461988D1 (en) 1983-05-06 1984-04-24 Parenteral formulation of nimodipin, process for its preparation and its therapeutical use

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8484104563T Expired DE3461988D1 (en) 1983-05-06 1984-04-24 Parenteral formulation of nimodipin, process for its preparation and its therapeutical use

Country Status (19)

Country Link
US (1) US5114956A (OSRAM)
EP (1) EP0126315B1 (OSRAM)
JP (1) JPS59206305A (OSRAM)
KR (1) KR920000306B1 (OSRAM)
AT (1) ATE24835T1 (OSRAM)
AU (1) AU562293B2 (OSRAM)
BE (1) BE899564A (OSRAM)
CA (1) CA1220424A (OSRAM)
DE (2) DE3316510A1 (OSRAM)
DK (1) DK164148C (OSRAM)
ES (1) ES8505542A1 (OSRAM)
FR (1) FR2545354B1 (OSRAM)
GR (1) GR81609B (OSRAM)
HK (1) HK75889A (OSRAM)
IL (1) IL71744A (OSRAM)
IT (1) IT1181804B (OSRAM)
PT (1) PT78542B (OSRAM)
SG (1) SG44489G (OSRAM)
ZA (1) ZA843352B (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3544692A1 (de) * 1985-12-18 1987-06-19 Bayer Ag Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
US5164405A (en) * 1989-02-28 1992-11-17 Syntex (U.S.A.) Inc. Nicardipine pharmaceutical composition for parenteral administration
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
WO2011095449A1 (de) 2010-02-05 2011-08-11 Basf Se Verfahren zur solubilisierung von hydrophoben wirkstoffen in wässrigem medium
US8728504B2 (en) 2010-02-05 2014-05-20 Basf Se Process for solubilizing hydrophobic active ingredients in aqueous medium

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60246313A (ja) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンの注射剤およびその製法
FR2585574B1 (fr) * 1985-07-31 1988-09-09 Corbiere Jerome Nouvelles compositions pharmaceutiques anti-glaucomateuses a base de 1,4-dihydropyridines et leur procede d'obtention
AT387518B (de) * 1985-12-18 1989-02-10 Bayer Ag Verfahren zur herstellung von fluessigen spruehpraeparaten von dihydropyridinen
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
CN1160115C (zh) * 1994-12-12 2004-08-04 奥默罗斯公司 用于抑制疼痛,炎症和痉挛的冲洗液和方法
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2007047406A2 (en) * 2005-10-14 2007-04-26 Transform Pharmaceuticals, Inc. Liquid pharmaceutical compositions of nimodipine
EP2015730A1 (de) * 2006-04-28 2009-01-21 Basf Se Verfahren zur solubilisierung von hydrophoben wirkstoffen in wässrigem medium
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
PT3442586T (pt) * 2016-04-13 2022-09-28 Acasti Pharma U S Inc Formulação parentérica estável de nimodipina
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
US20190255033A1 (en) 2018-02-22 2019-08-22 Nortic Holdings Inc. Stable Nimodipine Parenteral Formulation
US12414943B2 (en) 2022-05-16 2025-09-16 Grace Therapeutics U.S., Inc. Nimodipine parenteral administration
CN117502433A (zh) * 2023-11-08 2024-02-06 中国科学院海洋研究所 一种水母刺丝囊存放保护剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US4154839A (en) * 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
DE2650013C3 (de) * 1976-10-30 1981-04-02 Bayer Ag, 5090 Leverkusen 1.4-Dihydro-2.6-dimethyl-4-(3-nitrophenyl)-3.5-pyridindicarbonsäureisopropyl-(2-propoxy-äthyl)-ester, Verfahren zu seiner Herstellung sowie ihn enthaltende Arzneimittel
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE2841667A1 (de) * 1978-09-25 1980-04-10 Bayer Ag Fluorhaltige 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3544692A1 (de) * 1985-12-18 1987-06-19 Bayer Ag Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
US4857312A (en) * 1985-12-18 1989-08-15 Bayer Aktiengesellschaft Dihydropyridine spray, process for its preparation and its pharmaceutical use
US5164405A (en) * 1989-02-28 1992-11-17 Syntex (U.S.A.) Inc. Nicardipine pharmaceutical composition for parenteral administration
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
WO2011095449A1 (de) 2010-02-05 2011-08-11 Basf Se Verfahren zur solubilisierung von hydrophoben wirkstoffen in wässrigem medium
US8728504B2 (en) 2010-02-05 2014-05-20 Basf Se Process for solubilizing hydrophobic active ingredients in aqueous medium

Also Published As

Publication number Publication date
US5114956A (en) 1992-05-19
IT8448139A1 (it) 1985-11-04
IT1181804B (it) 1987-09-30
IT8448139A0 (it) 1984-05-04
AU562293B2 (en) 1987-06-04
AU2758384A (en) 1984-11-08
ES531995A0 (es) 1985-06-01
DK224184A (da) 1984-11-07
DK164148B (da) 1992-05-18
EP0126315B1 (de) 1987-01-14
ES8505542A1 (es) 1985-06-01
HK75889A (en) 1989-09-29
FR2545354A1 (fr) 1984-11-09
DK224184D0 (da) 1984-05-04
PT78542A (en) 1984-06-01
DE3461988D1 (en) 1987-02-19
IL71744A (en) 1988-04-29
FR2545354B1 (fr) 1986-09-26
EP0126315A1 (de) 1984-11-28
ZA843352B (en) 1984-12-24
SG44489G (en) 1989-11-17
JPH0422888B2 (OSRAM) 1992-04-20
IL71744A0 (en) 1984-09-30
PT78542B (en) 1986-07-14
KR920000306B1 (ko) 1992-01-11
BE899564A (fr) 1984-11-05
KR840009031A (ko) 1984-12-24
CA1220424A (en) 1987-04-14
DK164148C (da) 1992-10-26
GR81609B (OSRAM) 1984-12-11
ATE24835T1 (de) 1987-01-15
JPS59206305A (ja) 1984-11-22

Similar Documents

Publication Publication Date Title
DE3316510A1 (de) Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
EP0117888B2 (de) Flüssigzubereitungen von Dihydropyridinen, ein Verfahren zu ihrer Herstellung, sowie ihre Verwendung bei der Bekämpfung von Erkrankungen
DE2815578C2 (de) Neue pharmazeutische Verwendung von Nimodipin
DE69109021T2 (de) Augentropfenarzneimittel.
DE3886075T2 (de) Verwendung von Metformin zur Herstellung von Arzneimitteln.
DE2721171A1 (de) Neues vincaminsalz, seine herstellung und es enthaltende pharmazeutische zubereitungen
EP0185210A2 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE2515001C2 (de) Prostaglandin enthaltende gefriergetrocknete Pulver
DE68915269T2 (de) Polyvalentes entzündungshemmendes mittel.
DE2900203A1 (de) Krebshemmendes und krebsmetastasen verhinderndes arzneimittel
EP0143857A1 (de) Coronartherapeutikum in Form von Weichgelatine-Kapseln
DE3879575T2 (de) Alpha-Carotin zur Wachstumshemmung von Krebszellen.
DE3875324T2 (de) Dl-5-((2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidin-2,4-dion als antiatherosklerosemittel.
DE4203116A1 (de) Benzoylcarbinol und dessen ester, geeignet als inhibitoren der gefaessbildung
DE2951671A1 (de) Arzneimittelzubereitung
DE2209526C3 (de) Coronartherapeutlkum in Form von Gelatine-BeiBkapseln
DE3011274A1 (de) Synergistische strahlenschuetzende pharmazeutische praeparate sowie deren herstellung
DE1792764C3 (de) Coronarmittel
DE69532963T2 (de) Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen
DE1792448C3 (de) Verfahren zur Herstellung von zur parenteralen Verabreichung geeigneten stabilen Lösungen von therapeutisch anwendbaren Benzodiazepinderivaten
DE69208913T2 (de) 2-Oxindol-1-carboxamidderivat enthaltendes Arzneimittel zur rektalen Verabreichung
DE69228235T2 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE2234329A1 (de) Vincamin-derivat, verfahren zu seiner herstellung und diese verbindung enthaltende pharmazeutische zusammensetzungen
DE1695043C2 (de) Pharmazeutische Zusammensetzungen mit sedativen und tranquillisierenden Eigenschaften
DD283931A5 (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen

Legal Events

Date Code Title Description
8130 Withdrawal